Content area
Abstract
Gadolinium-based contrast agents (GBCAs) are widely used in medical imaging, with greater than 300 million doses administered since their introduction. The risk of adverse reactions is very low, and GBCAs were thought to be very safe until the discovery of nephrogenic systemic fibrosis (NSF). Since that time, gadolinium has been found to deposit throughout the body, including the brain, where it is visible on non-contrast T1-weighted MR images in people with normal renal function. The clinical effects of this deposition remain unknown and may not exist. In this review the authors provide a comprehensive update on GBCAs and their potential risks, within a historical context and through the lens of a pediatric radiologist.
Details
Title
Gadolinium-based contrast agents in children
Author
Rozenfeld, Michael N 1 ; Podberesky, Daniel J 2
1 Department of Radiology, University of Arizona College of Medicine – Phoenix, Phoenix, AZ, USA
2 Nemours Children’s Hospital, Nemours Children’s Health System, University of Central Florida College of Medicine, Orlando, FL, USA
1 Department of Radiology, University of Arizona College of Medicine – Phoenix, Phoenix, AZ, USA
2 Nemours Children’s Hospital, Nemours Children’s Health System, University of Central Florida College of Medicine, Orlando, FL, USA
Pages
1188-1196
Publication year
2018
Publication date
Aug 2018
ISSN
03010449
e-ISSN
14321998
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2082983011
Copyright
Pediatric Radiology is a copyright of Springer, (2018). All Rights Reserved.